The potential inhibitory role of teucrolivins against human dipeptidyl peptidase 4 protein as a promising strategy for treatment of type 2 diabetes
by Ateeq Ahmed Al-Zahrani
International Journal of Computational Biology and Drug Design (IJCBDD), Vol. 12, No. 4, 2019

Abstract: Inhibition of disease-related proteins by natural inhibitors revealed its efficiency and became a promising step in drug discovery. With hundreds of advanced web servers and software, it is possible to predict potential drug-target in order to reduce laboratory cost and time. In the current study, computational simulations were performed to investigate the possible role of teucrolivins, isolated from Teucrium oliverianum plant, as natural inhibitors against DP4 protein, which is related to type 2 diabetes. The docking results revealed that teucrolivin D showed higher binding affinities compared to the native inhibitor PF2 and other teucrolivins with the minimum binding energy of -144.16. Sitagliptin, vildagliptin and omarigliptin are antidiabetic drugs for inhibition of DP4 protein. They gave minimum binding energy of -120.19, -103.1 and -104.69 respectively, and showed a lower binding affinity compared to teucrolivin D. Evaluation of ADMET confirmed the capability of teucrolivin D as an effective inhibitor against DP4.

Online publication date: Wed, 13-Nov-2019

The full text of this article is only available to individual subscribers or to users at subscribing institutions.

 
Existing subscribers:
Go to Inderscience Online Journals to access the Full Text of this article.

Pay per view:
If you are not a subscriber and you just want to read the full contents of this article, buy online access here.

Complimentary Subscribers, Editors or Members of the Editorial Board of the International Journal of Computational Biology and Drug Design (IJCBDD):
Login with your Inderscience username and password:

Username:        Password:          Forgotten your password?

Want to subscribe?
A subscription gives you complete access to all articles in the current issue, as well as to all articles in the previous three years (where applicable). See our Orders page to subscribe.

If you still need assistance, please email subs@inderscience.com